Items per page
1 - 199 of 199
Title Published in Access level OA Policy Year Views Downloads
Rhumatismes inflammatoires : où en est-on avec les JAK-inhibiteurs ?Rheuma Plus / Schweiz
accessLevelPublic
2025 6 33
Identification of individuals at high risk of developing rheumatoid arthritis : a balanced random forest model in a cohort of 1544 first-degree relativesRMD open
accessLevelPublic
2025 7 22
ReplyArthritis & rheumatology
accessLevelRestricted
2025 8 0
Antibiotics in inflammatory arthritis and background population one year before and after diagnosis : a nationwide drug utilization studyRheumatology
accessLevelRestricted
2025 5 0
When borders impact science : what is the future of European rheumatology research ?Annals of the rheumatic diseases
accessLevelRestricted
2025 4 0
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study)Arthritis & rheumatology
accessLevelPublic
2025 79 49
Antirheumatic drugs in reproduction, pregnancy, and lactation : a systematic literature review informing the 2024 update of the EULAR recommendationsAnnals of the rheumatic diseases
accessLevelPublic
2025 17 280
The epidemiology of RANature reviews. Rheumatology
accessLevelRestricted
2025 5 0
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerAnnals of the rheumatic diseases
accessLevelRestricted
2025 45 0
Rhumatologie : ce qui a changé en 2023Revue médicale suisse
accessLevelPublic
2024 50 30
Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index : a cohort study in a Swiss registryBMJ open
accessLevelPublic
2024 8 14
Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis : the ROC-SpA study, a randomised controlled study protocolBMJ open
accessLevelPublic
2024 6 19
Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritisESC (Europan Society of Cardiology) Congress 2024
2024 4 0
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritisRMD open
accessLevelPublic
2024 105 63
Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis92nd EAS (European Atherosclerosis Society) Congress
2024 7 0
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)Annals of the rheumatic diseases
accessLevelPublic
2024 94 73
Explainable deep learning for disease activity prediction in chronic inflammatory joint diseasesPLOS digital health
accessLevelPublic
2024 6 10
Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritisFrontiers in cardiovascular medicine
accessLevelPublic
2024 114 150
Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RABMJ open
accessLevelPublic
2024 134 95
Tofacitinib Monotherapy in Rheumatoid Arthritis : Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment RetentionOpen access rheumatology
accessLevelPublic
2024 7 9
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesJoint bone spine
accessLevelPublic
2024 100 92
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerAnnals of the rheumatic diseases
accessLevelPublic
2024 56 430
Concomitant Sjögren's disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohortArthritis research & therapy
accessLevelPublic
2024 5 8
Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort studyFrontiers in medicine
accessLevelPublic
2023 67 83
Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximabRMD open
accessLevelPublic
2023 83 29
The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: predicting clinical arthritis developmentScandinavian journal of rheumatology
accessLevelPublic
2023 145 130
A potential role for chlamydial infection in rheumatoid arthritis developmentRheumatology
accessLevelPublic
2023 91 166
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyRheumatology
accessLevelPublic
2023 79 134
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAnnals of the rheumatic diseases
accessLevelPublic
2023 255 230
Characterization of serum biomarkers and antibody responses against Prevotella spp. in preclinical and new-onset phase of rheumatic diseasesFrontiers in cellular and infection microbiology
accessLevelPublic
2023 109 82
Brief report : assessment of mucosal barrier integrity using serological biomarkers in preclinical stages of rheumatoid arthritisFrontiers in immunology
accessLevelPublic
2023 184 211
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesArthritis research & therapy
accessLevelPublic
2023 67 137
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2023 130 81
Management of giant-cell arteritis in Switzerland: an online national surveySwiss medical weekly
accessLevelPublic
2023 230 230
Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumabJAMA neurology
accessLevelPublic
2022 244 160
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatologyAnnals of the rheumatic diseases
accessLevelPublic
2022 209 75
After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registriesAnnals of the rheumatic diseases
accessLevelPublic
2022 265 412
Nouveautés en médecine 2021 - RhumatologieRevue médicale suisse
accessLevelPublic
2022 295 205
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation studyAnnals of the rheumatic diseases
accessLevelPublic
2022 292 112
Periodontitis in first degree-relatives of individuals with rheumatoid arthritis: a short narrative reviewFrontiers in oral health
accessLevelPublic
2022 202 85
Prévention vaccinale chez les patients avec des maladies rhumatismalesRevue médicale suisse
accessLevelPublic
2022 110 104
Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohortPloS one
accessLevelPublic
2022 70 44
Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventionsStatistical methods in medical research
accessLevelPublic
2022 146 107
Global epidemiology of rheumatoid arthritisNature reviews. Rheumatology
accessLevelRestricted
2022 354 1
Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort StudyClinical infectious diseases
accessLevelPublic
2022 232 53
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaborationAnnals of the rheumatic diseases
accessLevelPublic
2022 337 96
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesFrontiers in immunology
accessLevelPublic
2022 203 76
Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : a descriptive cohort study assessing trends in patient characteristics in SwitzerlandBMJ open
accessLevelPublic
2022 61 49
Editoria : The interplay between the oral microbiota and rheumatoid arthritisFrontiers in oral health
accessLevelPublic
2022 108 68
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritisRheumatology
accessLevelPublic
2021 378 451
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsAnnals of the Rheumatic Diseases
accessLevelPublic
2021 250 719
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritisBMJ Open
accessLevelPublic
2021 354 154
Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patientsRheumatology advances in practice
accessLevelPublic
2021 160 89
Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in SwitzerlandJournal of Clinical Medicine
accessLevelPublic
2021 222 113
Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profilingInternational Journal of Immunogenetics
accessLevelRestricted
2021 215 0
Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatologyRMD open
accessLevelPublic
2021 262 143
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAnnals of the Rheumatic Diseases
accessLevelPublic
2021 185 227
Greater trochanteric pain syndrome: predicting who will respond to a local glucocorticoid injectionScandinavian Journal of Rheumatology
accessLevelRestricted
2021 255 0
Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritisRheumatology
accessLevelRestricted
2021 262 0
Primary and secondary non-response: in need of operational definitions in observational studiesAnnals of the Rheumatic Diseases
accessLevelPublic
2021 252 84
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countriesAnnals of the Rheumatic Diseases
accessLevelPublic
2021 207 282
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesRheumatology
accessLevelRestricted
2021 243 0
Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literatureThérapie
accessLevelRestricted
2021 1,166 1
Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trialBMJ open
accessLevelPublic
2021 250 143
Impact of assessing patient-reported outcomes with mobile apps on patient–provider interactionRMD Open
accessLevelPublic
2021 259 69
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximabRMD open
accessLevelPublic
2021 261 105
Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural networkPLOS ONE
accessLevelPublic
2021 294 185
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritisAnnals of the Rheumatic Diseases
accessLevelPublic
2021 373 107
Is the prevention of rheumatoid arthritis possible?Clinical Rheumatology
accessLevelRestricted
2020 177 0
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisArthritis Research and Therapy
accessLevelPublic
2020 413 333
EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseasesAnnals of the Rheumatic Diseases
accessLevelRestricted
2020 350 0
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional studyThe Lancet. Rheumatology
accessLevelPublic
2020 244 219
smarter medicine: liste Top-5 pour le traitement des rhumatismesBulletin des médecins suisses
accessLevelPublic
2020 118 66
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases
accessLevelPublic
2020 484 291
Measuring ACPA in the general population or primary care: is it useful?RMD Open
accessLevelPublic
2020 239 172
Mini-Review: Human Microbiome and Rheumatic DiseasesFrontiers in cellular and infection microbiology
accessLevelPublic
2020 193 179
Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-makingClinical Rheumatology
accessLevelRestricted
2020 205 0
Predictive factors of treatment persistence in rheumatoid arthritisJoint, Bone, Spine
accessLevelPublic
2020 422 634
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandRMD Open
accessLevelPublic
2020 217 97
Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real lifeJoint, Bone, Spine
accessLevelRestricted
2020 359 0
The role of nutritional factors and intestinal microbiota in rheumatoid arthritis developmentNutrients
accessLevelPublic
2020 169 179
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseRheumatology
accessLevelRestricted
2020 324 8
Periodontal status correlates with anti‐citrullinated protein antibodies in first‐degree relatives of individuals with rheumatoid arthritisJournal of Clinical Periodontology
accessLevelRestricted
2019 423 2
Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysisClinical and Experimental Rheumatology
accessLevelPublic
2019 383 187
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionRheumatology
accessLevelRestricted
2019 371 0
EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseasesRMD Open
accessLevelPublic
2019 335 190
Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?RMD Open
accessLevelPublic
2019 334 147
Menopause and possible effect on association between age and anticyclic citrullinated peptide antibodies in women at risk of rheumatoid arthritisJournal of Rheumatology
accessLevelRestricted
2019 301 0
Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three yearsRheumatology
accessLevelPublic
2019 308 174
Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trialClinical Rheumatology
accessLevelRestricted
2019 315 0
The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritisBritish Journal of Haematology
accessLevelRestricted
2019 258 0
Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohortRheumatology
accessLevelRestricted
2019 270 0
2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritisAnnals of the Rheumatic Diseases
accessLevelPublic
2019 344 262
Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metricQuality of Life Research
accessLevelPublic
2019 272 145
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countriesAnnals of the Rheumatic Diseases
accessLevelRestricted
2019 364 0
Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritisRMD Open
accessLevelPublic
2019 337 101
Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individualsPLOS ONE
accessLevelPublic
2019 307 238
Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendationsRMD Open
accessLevelPublic
2019 342 137
Prevotella copri in individuals at risk for rheumatoid arthritisAnnals of the Rheumatic Diseases
2019 466 0
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid ArthritisClinical Therapeutics
accessLevelRestricted
2019 293 1
Intestinal dysbiosis in RA development: difficulty of establishing causality. Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by InamoAnnals of the Rheumatic Diseases
accessLevelRestricted
2019 340 4
Lessons learned from rheumatoid arthritis registriesJoint, Bone, Spine
accessLevelRestricted
2018 444 3
Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR projectRMD Open
accessLevelPublic
2018 462 194
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to considerRMD Open
accessLevelPublic
2018 319 224
EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatologyRMD Open
accessLevelPublic
2018 319 206
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss CohortJournal of Rheumatology
accessLevelRestricted
2018 460 1
Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid ArthritisMedical Decision Making
accessLevelRestricted
2018 474 0
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritisAnnals of the Rheumatic Diseases
accessLevelRestricted
2018 427 0
Microbiotes et rhumatismes inflammatoiresRevue médicale suisse
accessLevelPublic
2018 499 158
Chagas disease and systemic autoimmune diseases among Bolivian patients in SwitzerlandMemórias do Instituto Oswaldo Cruz
accessLevelPublic
2018 599 213
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III TrialArthritis Care and Research
accessLevelRestricted
2018 366 1
Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritisArthritis Care and Research
accessLevelPublic
2018 435 433
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 550 5
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersAnnals of the Rheumatic Diseases
accessLevelPublic
2017 500 241
Value of Biomarkers in the Prevention of Rheumatoid ArthritisClinical Pharmacology and Therapeutics
accessLevelRestricted
2017 456 0
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritisClinical Rheumatology
accessLevelRestricted
2017 629 3
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases
accessLevelRestricted
2017 482 2
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)Clinical Rheumatology
accessLevelRestricted
2017 406 0
Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotypePloS one
accessLevelPublic
2017 559 304
Environmental factors and hormones in the development of rheumatoid arthritisSeminars in Immunopathology
accessLevelRestricted
2017 480 0
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Clinical Rheumatology
accessLevelRestricted
2017 481 2
The role of female hormonal factors in the development of rheumatoid arthritisRheumatology
accessLevelRestricted
2017 467 0
Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of lifeQuality of life research
accessLevelRestricted
2017 524 1
New viral outbreaks: time for rheumatologists to get involved?Rheumatology
accessLevelRestricted
2017 462 0
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAnnals of the rheumatic diseases
accessLevelRestricted
2016 593 0
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisArthritis & rheumatology
accessLevelRestricted
2016 527 0
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiativeAnnals of the Rheumatic Diseases
accessLevelRestricted
2016 456 0
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary ReportThe New England journal of medicine
accessLevelPublic
2016 932 275
Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational studyJoint, Bone, Spine
accessLevelRestricted
2016 535 0
Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient PreferencesCurrent rheumatology reports
accessLevelRestricted
2016 561 1
Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry AnalysisArthritis and Rheumatology
accessLevelRestricted
2016 381 0
Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort StudyEBioMedicine
accessLevelPublic
2016 485 204
Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-AnalysisJournal of managed care & specialty pharmacy
accessLevelRestricted
2015 588 0
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management RegistryRheumatology
accessLevelRestricted
2015 499 0
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registersRheumatology
accessLevelPublic
2015 599 291
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialLancet. Infectious diseases
accessLevelRestricted
2015 705 0
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritisClinical rheumatology
accessLevelRestricted
2015 566 0
An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeksClinical rheumatology
accessLevelRestricted
2015 472 0
Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteriaRheumatology international
accessLevelRestricted
2015 599 0
Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort studyAnnals of the rheumatic diseases
accessLevelRestricted
2015 645 0
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness studyAnnals of the rheumatic diseases
accessLevelPublic
2015 569 323
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesRMD open
accessLevelPublic
2015 481 248
Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort StudyInflammatory bowel diseases
accessLevelRestricted
2015 492 0
The impact of obesity on the development and progression of rheumatoid arthritisAnnals of the rheumatic diseases
accessLevelRestricted
2014 561 0
Immune-mediated experimental arthritis in IL-33 deficient miceCytokine
accessLevelRestricted
2014 675 0
Prevention of rheumatic diseases: strategies, caveats, and future directionsRheumatic diseases clinics of North America
2014 492 0
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and kneeInternational orthopaedics
accessLevelRestricted
2014 579 0
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UKPharmacoEconomics
accessLevelPublic
2014 525 501
Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?Journal of rheumatology
accessLevelRestricted
2014 525 0
Facteurs de risque pour le développement d'une polyarthrite rhumatoïdeRevue médicale suisse
accessLevelRestricted
2014 532 2
Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort studyAnnals of the rheumatic diseases
accessLevelPublic
2014 616 605
Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort studyJoint bone spine
accessLevelRestricted
2014 593 0
Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trialArthritis research & therapy
accessLevelPublic
2014 706 229
Complications cardio-vasculaires dans les maladies auto-immunesRevue médicale suisse
accessLevelRestricted
2013 547 1
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registryJoint bone spine
accessLevelRestricted
2013 559 0
Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiencyArthritis research & therapy
accessLevelPublic
2013 645 282
Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk populationJoint bone spine
accessLevelRestricted
2013 626 1
Do synovial leptin levels correlate with pain in end stage arthritis?International orthopaedics
accessLevelPublic
2013 674 208
Smoking and spondyloarthritisJoint bone spine
accessLevelRestricted
2013 562 1
The importance of early treatment for the prognosis of rheumatoid arthritisSchweizerische medizinische Wochenschrift
accessLevelPublic
2013 656 306
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trialAnnals of the rheumatic diseases
accessLevelRestricted
2012 672 0
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsAnnals of the rheumatic diseases
accessLevelPublic
2012 564 428
Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?Arthritis care & research
accessLevelRestricted
2012 695 0
Pain as an important predictor of psychosocial health in patients with rheumatoid arthritisArthritis care & research
accessLevelPrivate
2012 661 0
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisAnnals of the rheumatic diseases
accessLevelPublic
2012 700 570
Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patientsAnnals of the rheumatic diseases
accessLevelRestricted
2012 678 0
Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infectionMicrobes and infection
accessLevelRestricted
2011 617 0
Patient repositioning reproducibility of joint space with (JSW) measurements on hand radiographsArthritis care & research
accessLevelRestricted
2011 483 0
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single centerArthritis and rheumatism
accessLevelRestricted
2011 686 0
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyRheumatology
accessLevelRestricted
2011 607 0
Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritisArthritis and rheumatism
accessLevelRestricted
2011 645 0
Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletionRheumatology
accessLevelRestricted
2011 510 0
Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysisAnnals of the rheumatic diseases
accessLevelRestricted
2011 588 0
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyAnnals of the rheumatic diseases
accessLevelRestricted
2010 591 0
Osteoarthritis: Small studies overestimate the benefit of therapies for OANature reviews. Rheumatology
accessLevelRestricted
2010 688 0
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patientsJoint bone spine
accessLevelRestricted
2010 618 0
Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patientsArthritis research & therapy
accessLevelPublic
2010 788 554
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 903 3
Cost-effectiveness of biologics in early rheumatoid arthritisAnnals of internal medicine
2010 523 0
The effect of alcohol on radiographic progression in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2010 596 0
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the rheumatic diseases
accessLevelRestricted
2010 595 0
Comparative effectiveness of rheumatoid arthritis therapiesCurrent rheumatology reports
accessLevelRestricted
2010 523 0
Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritisSchweizerische medizinische Wochenschrift
2010 569 0
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesSeminars in arthritis and rheumatism
accessLevelRestricted
2010 632 0
Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trialArthritis and rheumatism
accessLevelRestricted
2010 674 0
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisArthritis and rheumatism
accessLevelRestricted
2009 658 0
Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapiesSchweizerische medizinische Wochenschrift
accessLevelPublic
2009 632 333
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis and rheumatism
accessLevelRestricted
2009 627 0
BMI and severity of clinical and radiographic signs of hip osteoarthritisObesity
accessLevelRestricted
2009 988 0
Influence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniationArthritis research & therapy
accessLevelPublic
2009 664 241
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based studyAnnals of the rheumatic diseases
accessLevelRestricted
2009 610 0
Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated discSpine
accessLevelRestricted
2008 678 0
At the horizon of innovative therapy in rheumatology: new biologic agentsCurrent opinion in rheumatology
accessLevelRestricted
2008 629 0
Primer: strengths and weaknesses of meta-analysisNature clinical practice rheumatology
accessLevelRestricted
2008 670 0
Neutral functional realignment orthosis prevents hand pain in patients with subacute stroke: a randomized trialArchives of physical medicine and rehabilitation
accessLevelRestricted
2008 603 0
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agentsArthritis and rheumatism
accessLevelRestricted
2007 178 1
Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban womenArthritis and rheumatism
accessLevelPublic
2006 243 501
Fibromyalgia: a randomised, controlled trial of a treatment programme based on self managementAnnals of the rheumatic diseases
accessLevelRestricted
2004 508 2
Neurophysiologic evidence for a central sensitization in patients with fibromyalgiaArthritis and rheumatism
accessLevelPublic
2003 544 850
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack